slave1, a question. "• Patient-specific ATMP kits (like DCVax-L + Hiltonol) to be manufactured and delivered without full MHRA approval, so long as each dose is labeled for a named patient."
Does this mean for glioblastoma only or can this be interpreted for mult cancer tumors?
Market Data 
Markets 
AI
